Investment Thesis
Palisade Bio is a pre-revenue biotech with exceptionally strong financial health: $132.6M cash, minimal debt, and a 34+ year cash runway at current burn rates. However, zero revenue and lack of visible commercialization pathway limit upside assessment; the 97.1% YoY improvement in EPS losses suggests operational discipline, but fundamental progress remains elusive.
Strengths
- Exceptional liquidity position with $132.6M cash (99.5% of total assets) and 23.71x current ratio
- Minimal debt burden ($87K long-term) and fortress balance sheet with $127.4M stockholders' equity
- Significant 97.1% YoY improvement in diluted EPS losses, indicating operational efficiency gains
Risks
- Zero revenue with no evidence of commercial product viability or market acceptance
- Negative operating cash flow of $3.9M annually indicates persistent capital burn without offsetting revenue
- Pre-revenue biotech status with unclear clinical pipeline, regulatory approval timeline, and path to profitability
Key Metrics to Watch
- Revenue generation timeline and first commercial product launch milestones
- Operating cash burn rate trajectory and remaining cash runway sustainability
- Clinical development pipeline progression and regulatory approval status
Financial Metrics
Revenue
0.0
Net Income
-9.6M
EPS (Diluted)
$-0.05
Free Cash Flow
-3.9M
Total Assets
133.3M
Cash
132.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-7.5%
ROA
-7.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
23.71x
Quick Ratio
23.71x
Debt/Equity
0.00x
Debt/Assets
4.5%
Interest Coverage
-1,343.50x
Long-term Debt
87.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T09:05:00.713137 |
Data as of: 2026-03-31 |
Powered by Claude AI